tbuckley/cabot-search huggingface dataset:
Histone methyltransferase Nsd2 is required for follicular helper T cell differentiation
Authors: Xuehui Long, Le Zhang, Yang Zhang, Min Min, Bichun Lin, Jingjing Chen, Xiaojie Ma, Sulan Zhai, Zhenming Cai, Yingxia Liu, Yanlai Lu, Nan Che, Wenfeng Tan, Jun Qin, Xiaoming Wang
Journal: The Journal of Experimental Medicine (2019)

Follicular helper T (Tfh) cells provide essential help for humoral immune response. Transcriptional factor Bcl6 is the master regulator for Tfh generation and is induced very early after T cell activation in a CD28-dependent manner, but how CD28 signal promotes Bcl6 early expression remains unknown. Here we found that CD28 signal quickly induces expression of the H3K36me2 methytransferase Nsd2, which is required for Bcl6 expression as early as the first cell division after T cell activation. Nsd2 deficiency in T cells leads to decreased Bcl6 expression, impaired Tfh generation, compromised germinal center response, and delayed virus clearance. Ectopic Bcl6 expression rescues the Tfh defect of Nsd2 KO cells. ICOS signal is dispensable for early Nsd2 induction but required for sustained Nsd2 expression, which is critical for Tfh maintenance. Overexpression of Nsd2 increases Bcl6 expression and enhances Tfh generation; 4-mo-old mice even develop spontaneous Tfh. Overall, our study reveals Nsd2 as a critical epigenetic regulator for Tfh differentiation.
P2.14-26 Outcomes in Patients with Compound Epidermal Growth Factor Receptor (EGFR) Mutations After Treatment with Tyrosine Kinase Inhibitors (TKIs)
Authors: S. Breslin, J. Thompson, J. Morrissette, C. Ciunci, A. Singh, C. Aggarwal, R. Cohen, C. Langer, J. Bauml, M. Marmarelis
Journal: Journal of Thoracic Oncology (2019)
Higher Gene Flow in Sex-Related Chromosomes than in Autosomes during Fungal Divergence
Authors: Fanny E Hartmann, Ricardo C Rodríguez de la Vega, Pierre Gladieux, Wen-Juan Ma, Michael E Hood, Tatiana Giraud
Journal: Molecular Biology and Evolution (2019)

Nonrecombining sex chromosomes are widely found to be more differentiated than autosomes among closely related species, due to smaller effective population size and/or to a disproportionally large-X effect in reproductive isolation. Although fungal mating-type chromosomes can also display large nonrecombining regions, their levels of differentiation compared with autosomes have been little studied. Anther-smut fungi from the Microbotryum genus are castrating pathogens of Caryophyllaceae plants with largely nonrecombining mating-type chromosomes. Using whole genome sequences of 40 fungal strains, we quantified genetic differentiation among strains isolated from the geographically overlapping North American species and subspecies of Silene virginica and S. caroliniana. We inferred that gene flow likely occurred at the early stages of divergence and then completely stopped. We identified large autosomal genomic regions with chromosomal inversions, with higher genetic divergence than the rest of the genomes and highly enriched in selective sweeps, supporting a role of rearrangements in preventing gene flow in genomic regions involved in ecological divergence. Unexpectedly, the nonrecombining mating-type chromosomes showed lower divergence than autosomes due to higher gene flow, which may be promoted by adaptive introgressions of less degenerated mating-type chromosomes. The fact that both mating-type chromosomes are always heterozygous and nonrecombining may explain such patterns that oppose to those found for XY or ZW sex chromosomes. The specific features of mating-type chromosomes may also apply to the UV sex chromosomes determining sexes at the haploid stage in algae and bryophytes and may help test general hypotheses on the evolutionary specificities of sex-related chromosomes.
P2.01-58 Detection of Kras Mutation from Urine of Indonesian Lung Cancer Patients
Authors: A. Ridwanuloh, F. Fadiyah, F. Patria, R. Yasril, A. Hudoyo, J. Zaini, S. Andarini, N. Masykura, A. Utomo
Journal: Journal of Thoracic Oncology (2019)
P2.03-33 ctDNA Levels Significantly Predicts Survival in NSCLC Patients with an EGFR Activating Mutation
Authors: E. Sánchez Herrero, F. Franco, M. Auglite, R. Serna Blasco, M. Barquín Del Romo, A. Sanchez-Hernandez, C. Garcia Giron, M. Domine, E. Jantus, C. Camps, J.M. Sánchez, J. Oramas, L.E. Chara, A.L. Ortega, M.a. Sala, B. Hernandez, M. Sereno, J. Bosch-Barrera, A. Padilla, J. Balsalobre, R. Blanco, J. De Castro Carpeno, X. Mielgo Rubio, M. Sotelo, J. Coves, V. Calvo De Juan, M. Provencio, A. Romero
Journal: Journal of Thoracic Oncology (2019)
Use of Illicit Drugs Continues to Rise
Authors: Rita Rubin
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OA08.01 Organoid Cultures as Novel Preclinical Models of Non-Small Cell Lung Cancer
Authors: M. Tsao, R. Shi, N. Radulovich, C. Ng, H. Notsuda, M. Cabanero, S. Martins-Filho, V. Raghavan, Q. Li, A. Mer, N. Liu, N. Pham, B. Haibe-Kains, G. Liu, N. Moghal
Journal: Journal of Thoracic Oncology (2019)
Delayed Retinal Breaks and Detachments after Acute Posterior Vitreous Detachment
Authors: Joshua H. Uhr, Anthony Obeid, Turner D. Wibbelsman, Connie M. Wu, Hannah J. Levin, Hannah Garrigan, Marc J. Spirn, Allen Chiang, Arunan Sivalingam, Jason Hsu
Journal: Ophthalmology (2019)
EP1.01-24 Lung Adenocarcinoma: Mutational Profile in Ever Smokers and Non-Smokers Patients
Authors: D. Reis, C. Marques, D. Coutinho, E. Silva, M. Dias, T. Costa, S. Campainha, S. Conde, L. Cirnes, A. Barroso
Journal: Journal of Thoracic Oncology (2019)
JCSE01.24 Dynamic Changes of Plasma PD-L1 mRNA Expression Predict Response to Anti-PD-1/Anti-PD-L1 Treatment in Malignancies
Authors: J. Sun, Q. Yang, M. Chen, J. Gu, L. Zheng, Y. Yu, F. Li, L. Zhang, K. Niu
Journal: Journal of Thoracic Oncology (2019)
Authors’ reply to Mahmood, Borumandi, and Williams
Authors: Neeti Ghali, Glenda Sobey, Nigel Burrows
Journal: BMJ (2019)

The main purpose of our paper was to inform readers of the protean manifestations of Ehlers-Danlos syndromes (EDS) and how to approach a patient with a possible diagnosis of EDS. It was not possible to cover in depth the complex associations with hypermobile EDS, …
Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients with Myelodysplastic Syndromes (MDS) after Failure of Hypomethylating Agent-Based Therapy
Authors: Sangmin Lee, Pinkal Desai, Bianca Edirisinghe, Samantha Pianello, Jack W. Singer, Michael Samuel, Ellen K Ritchie, Gail J. Roboz
Journal: Blood (2017)
High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib
Authors: A. R. Mir, S. Sazawal Sazawal, A. Saxena, R. Saxena
Journal: Journal of Clinical Oncology (2009)

7061 Objectives: (1) To study the detection of M351T, F317L, and F311C ABL kinase domain mutation in CML patients treated with TKIs (imatinib and dasatinib). (2) To evaluate the effect of imatinib dose esculation in the CML patients carrying M351T mutations. Methods: One hundred CML patients were treated with imatinib at 400 mg/day from 2 to 4 years .They were diagnosed by RT-PCR for BCR-ABL transcripts. Early screening for the M351T, F317L, and F311C mutations was performed by allele specific-oligonucleotide-PCR (ASO-PCR). Results: We evaluated 100 CML patients for kinase domain mutation by ASO-PCR after three years of imatinib initiation. Patients were categorized into three groups. Group A All 100 CML patients were treated with imatinib at conventional dose of 400 mg/day and were screened for M351T mutation after three years of imatinib initiation. (40%) 40/100 were positive for M351T mutation consequently 20/40 were treated with high dose imatinib at 600 to 800 or 1,000 mg/day. After 11 months of dose escalation, 15/20 lost M351T mutation but remaining five who resist M351T mutation, developed a more fatal mutation called gate keeper mutation T315I. 2/5 died, three progressed to advanced disease. Group B All 100 CML patients were screened for F311C mutation after three years of imatinib initiation and (10%) 10/100 were positive. After 10 months, 4/10 developed a more fatal mutation in 315 and consequently 2/4 died and one progressed to advanced disease. Group C It included 12 imatinib-resistant CML patients treated with dasatinib at 70 to 100 mg/day. At the initiation of dasatinib, no one was positive for F317L and T315I mutation. After 10 months of dasatinib treatment, all were screened for F317L/ T315I mutation by ASO-PCR, 4/12 were positive for F317L mutation and no one was positive for T315I mutation. After 6 months of mutation detection 2/4 progressed to blast crisis, and 1/4 died. Conclusions: ASO-PCR proved to be a very economical, sensitive, and rapid technique for detection of KD mutations M351T, F317L, and F311C ABL mutation and is more sensitive than mutation detection by sequencing. The detection of M351T, F317L, and F311C -ABL mutation at any stage has prognostic significance. No significant financial relationships to disclose.
MA09.07 Activity of Larotrectinib in TRK Fusion Lung Cancer
Authors: A. Farago, S. Kummar, V. Moreno, J. Patel, U. Lassen, L. Rosen, N. Ku, M. Cox, S. Nanda, B. Childs, D. Hyman, A. Drilon
Journal: Journal of Thoracic Oncology (2019)
P1.03-47 KEAP1 Mutations in East Asian Patients with NSCLC: An Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis
Authors: Z. Yu, C. Xu, W. Wang, Q. Zhang, W. Zhuang, Y. Zhu, Z. Huang, G. Chen, M. Fang, T. Lv, Y. Song
Journal: Journal of Thoracic Oncology (2019)
P1.18-01 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
Authors: S. Aix, S. Novello, E. Garon, K. Nakagawa, E. Nadal, D. Moro-Sibilot, M. Alonso Garcia, E. Fabre, B. Frimodt-Moller, A. Zimmermann, C. Visseren-Grul, M. Reck
Journal: Journal of Thoracic Oncology (2019)
P2.04-74 Radiotherapy Prior to Immunotherapy Is Associated with Durable Disease Control in Advanced NSCLC
Authors: Å. Öjlert, M. Lund-Iversen, R. Åstrøm Ellefsen, M. Sprauten, O.T. Brustugun, V. Flote, A.R. Halvorsen, Å. Helland
Journal: Journal of Thoracic Oncology (2019)
P2.14-62 Early, Subclinical SCLC Transformation in Patients with EGFR Mutant Lung Cancer Receiving Osimertinib, Detected Through Cell-Free DNA
Authors: E. Stewart, S. Martins-Filho, M. Cabanero, A. Wang, J. Huang, H. Bao, X. Wu, D. Patel, Z. Chen, J. Law, P. Bradbury, F. Shepherd, N. Leighl, M. Tsao, T. Pugh, S. Bratman, G. Liu, A. Sacher
Journal: Journal of Thoracic Oncology (2019)
EP1.12-10 Molecular Characterization of NSCLC-Like and SCLC-Like Subsets in Chinese Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC)
Authors: L. Wu, L. Cao, L. Chen, B. Zhu, X. Hu, G. Lin, Y. Lin, S. Zhang, W. Peng, M. Jiang, X. Mao, T. Zhang, J. Ye, L. Zhang
Journal: Journal of Thoracic Oncology (2019)
P1.04-82 Toxicity as a Clinical Marker for Efficacy of Immunotherapy in NSCLC: A Multicentric Experience from Argentina
Authors: M. Rizzi, M. Rizzo, N. Minatta, G. Recondo, M. Naveira, L. Lupinacci, A. Kuzminin, M. Faura, A. Perfetti, S. Sena, M. Bluthgen
Journal: Journal of Thoracic Oncology (2019)
P1.03-07 Advantages and Setbacks of EGFR Mutation Testing from Liquid Biopsy of Advanced Lung Adenocarcinoma Patients in Serbia
Authors: J. Spasic, A. Krivokuca, I. Boljevic, M. Pavlovic, J. Rakobradovic, V. Jokic, D. Radosavljevic, E. Malisic, R. Jankovic, M. Cavic
Journal: Journal of Thoracic Oncology (2019)
P1.01-40 EGFR ctDNA Detection: The Impact of Site of Progression and Burden of Progressive Disease
Authors: A. Pender, C. Hughesman, E. Law, A. Kristanti, K. Mcneil, T. Tucker, I. Bosdet, S. Young, J. Laskin, A. Karsan, S. Yip, C. Ho
Journal: Journal of Thoracic Oncology (2019)
EP1.01-21 Time on Treatment of First-Line PD-1 Inhibitor Monotherapy for Metastatic Non-Small Cell Lung Cancer Patients: Real-World Experience Data
Authors: L. Apter, S. Sharman Moser, S. Chandwani, X. Chen, V. Shalev, G. Chodick, N. Siegelmann-Danieli
Journal: Journal of Thoracic Oncology (2019)
EP1.16-16 Pembrolizumab as First Therapeutic Line in Non-Small Cell Lung Cancer – The Experience of a Portuguese Tertiary Hospital
Authors: N. China Pereira, A. Mendes, D. Reis, M. Dias, D. Coutinho, T. Costa, E. Silva, S. Campainha, S. Conde, A. Barroso
Journal: Journal of Thoracic Oncology (2019)
Clinical Outcomes up to 3 Years Following Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar Hgb-204 Study
Authors: Janet L. Kwiatkowski, Alexis A Thompson, John Rasko, Suradej Hongeng, Gary J. Schiller, Usanarat Anurathapan, Marina Cavazzana, Phoebe Joy Ho, Christof von Kalle, Morris Kletzel, Philippe Leboulch, Elliott Vichinsky, Briana Deary, Mohammed Asmal, Mark C. Walters
Journal: Blood (2017)
Brain Damage With Heart Failure
Authors: Karsten Mueller, Friederike Thiel, Frank Beutner, Andrej Teren, Stefan Frisch, Tommaso Ballarini, Harald E. Möller, Kristin Ihle, Joachim Thiery, Gerhard Schuler, Arno Villringer, Matthias L. Schroeter
Journal: Circulation Research (2020)

Heart failure (HF) following heart damage leads to a decreased blood flow due to a reduced pump efficiency of the heart muscle. A consequence can be insufficient oxygen supply to the organism including the brain. While HF clearly shows neurological symptoms, such as fatigue, nausea, and dizziness, the implications for brain structure are not well understood. Few studies show regional gray matter decrease related to HF; however, the underlying mechanisms leading to the observed brain changes remain unclear.To study the relationship between impaired heart function, hampered blood circulation, and structural brain change in a case-control study.Within a group of 80 patients of the Leipzig Heart Center, we investigated a potential correlation between HF biomarkers and the brain's gray matter density (GMD) obtained by magnetic resonance imaging. We observed a significant positive correlation between cardiac ejection fraction and GMD across the whole frontal and parietal medial cortex reflecting the consequence of HF onto the brain's gray matter. Moreover, we also obtained a relationship between GMD and the NT-proBNP (N-terminal prohormone of brain natriuretic peptide)-a biomarker that is used for screening, diagnosis, and prognosis of HF. Here, we found a significant negative correlation between NT-proBNP and GMD in the medial and posterior cingulate cortex but also in precuneus and hippocampus, which are key regions implicated in structural brain changes in dementia.We obtained significant correlations between brain structure and markers of heart failure including ejection fraction and NT-proBNP. A diminished GMD was found with decreased ejection fraction and increased NT-proBNP in wide brain regions including the whole frontomedian cortex as well as hippocampus and precuneus. Our observations might reflect structural brain damage in areas that are related to cognition; however, whether these structural changes facilitate the development of cognitive alterations has to be proven by further longitudinal studies.
P1.01-23 Retrospective Analysis of Real-World Clinico-Genomic Data for Clinical Impact of Genomic Profiling of ctDNA in NSCLC
Authors: R. Madison, A. Schrock, J. Gregg, K. Carson, E. Castellanos, G. Singal, V. Miller, S. Ali, B. Alexander, J. Chung
Journal: Journal of Thoracic Oncology (2019)
A roadmap for management of chronic thromboembolic pulmonary hypertension
Authors: Xavier Jaïs, Philippe Brenot, David Montani, Elie Fadel, Marc Humbert, Gérald Simonneau
Journal: European Respiratory Journal (2019)

In a recent editorial published in the European Respiratory Journal , Lang and Matsubara [1] comment on the French experience of balloon pulmonary angioplasty (BPA) for inoperable chronic thromboembolic pulmonary hypertension (CTEPH) in the context of international BPA experience [2]. The groundbreaking development of BPA techniques (initially developed in the USA by Feinstein et al. [3]) is widely recognised, and Matsubara and his Japanese colleagues should be congratulated for refining this treatment [4]. In the mid-2010s, BPA was implemented in high-volume expert centres in Europe, including France and Germany [2, 5]. Multicentre consortia should now produce stronger data both from randomised controlled trials and multicentre registries, in order to implement CTEPH guidelines <http://bit.ly/2TWnaJ3>
Older Patients (Still) Left Out of Cancer Clinical Trials
Authors: Jennifer Abbasi
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Endoscopic ultrasound-guided gastrojejunostomy-assisted ERCP in a Billroth II gastrectomy patient
Authors: Belén Martínez-Moreno, Juan Antonio Casellas, José Ramón Aparicio Tormo
Journal: Endoscopy (2019)

An 85-year-old man who had previously undergone a Billroth II gastrectomy was admitted because of biliary sepsis due to choledocholithiasis. An urgent percutaneous cholecystostomy was performed and endoscopic retrograde cholangiopancreatography (ERCP) was requested. The afferent limb was however not accessible with either the duodenoscope or a therapeutic gastroscope because of the sharp angulation and a long afferent limb ([Fig. 1 a]). An 8.5-Fr nasobiliary tube was advanced into the afferent limb to distend it with contrast and methylene blue ([Fig. 1 b]). An echoendoscope was then introduced and, after the afferent limb closest to the papilla had been identified ([Fig. 2]), an endoscopic ultrasound-guided gastrojejunostomy (EUS-GJ) was performed using a 15 × 10-mm lumen-apposing metal stent (LAMS; Hot Axios; Boston Scientific, Natick, Massachusetts, USA) ([Fig. 3]).
EP1.04-10 Nivolumab in Non-Small Cell Lung Cancer (NSCLC): A Real-Life Study
Authors: D. Reis, A. Mendes, N. China, M. Dias, D. Coutinho, E. Silva, S. Campainha, T. Costa, S. Conde, A. Barroso
Journal: Journal of Thoracic Oncology (2019)
P2.16-43 Immunotherapy in Elderlies. Real World Data
Authors: L.F. Sánchez-Cousido, M. Rojas Piedra, M. López Flores, I. Delgado Sillero, A. López González, C. Castañón, B. Nieto Mangudo, M. Pedraza, L. De Sande, S. Medina, Á. Rodriguez, A. García-Palomo, P. Diz Tain
Journal: Journal of Thoracic Oncology (2019)
Five-Year Clinical and Echocardiographic Outcomes From the NOTION Randomized Clinical Trial in Patients at Lower Surgical Risk
Authors: Hans Gustav Hørsted Thyregod, Nikolaj Ihlemann, Troels Højsgaard Jørgensen, Henrik Nissen, Bo Juel Kjeldsen, Petur Petursson, Yanping Chang, Olaf Walter Franzen, Thomas Engstrøm, Peter Clemmensen, Peter Bo Hansen, Lars Willy Andersen, Daniel Andreas Steinbruüchel, Peter Skov Olsen, Lars Søndergaard
Journal: Circulation (2019)

Background: The NOTION trial (Nordic Aortic Valve Intervention) was designed to compare transcatheter aortic valve replacement (TAVR) with surgical aortic valve replacement (SAVR) in patients ≥70 years old with isolated severe aortic valve stenosis. Clinical and echocardiographic outcomes are presented after 5 years. Methods: Patients were enrolled at 3 Nordic centers and randomized 1:1 to TAVR using the self-expanding CoreValve prosthesis (n=145) or SAVR using any stented bioprostheses (n=135). The primary composite outcome was the rate of all-cause mortality, stroke, or myocardial infarction at 1 year defined according to Valve Academic Research Consortium-2 criteria. Results: Baseline characteristics were similar. The mean age was 79.1±4.8 years and mean Society of Thoracic Surgeons Predicted Risk of Mortality score was 3.0%±1.7%. After 5 years, there were no differences between TAVR and SAVR in the composite outcome (Kaplan-Meier estimates 38.0% versus 36.3%, log-rank test P =0.86) or any of its components. TAVR patients had larger prosthetic valve area (1.7 cm 2 versus 1.2 cm 2 , P &lt;0.001) with a lower mean transprosthetic gradient (8.2 mm Hg versus 13.7 mm Hg, P &lt;0.001), both unchanged over time. More TAVR patients had moderate/severe total aortic regurgitation (8.2% versus 0.0%, P &lt;0.001) and a new pacemaker (43.7% versus 8.7%, P &lt;0.001). Four patients had prosthetic reintervention and no difference was found for functional outcomes. Conclusions: These are currently the longest follow-up data comparing TAVR and SAVR in lower risk patients, demonstrating no statistical difference for major clinical outcomes 5 years after TAVR with a self-expanding prosthesis compared to SAVR. Higher rates of prosthetic regurgitation and pacemaker implantation were seen after TAVR. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT01057173.
P2.14-15 Impact of Coexisting Gene Mutations in EGFR-Mutated Non–Small Cell Lung Cancer Before Treatment on EGFR T790M Mutation Status After EGFR-TKIs
Authors: M. Takeda, K. Sakai, H. Hayashi, K. Tanaka, K. Haratani, T. Takahama, R. Kato, K. Yonesaka, K. Nishio, K. Nakagawa
Journal: Journal of Thoracic Oncology (2019)
EP1.15-11 Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center
Authors: N. Ak, A. Toker, S. Bayraktar, B. Özkan, M. Ülker, N. Dağoğlu, S. Karaman, E. Kaba, F. Ferhatoğlu, E. Aydın, E. Kaytan Sağlam, E. Nezih Oral, G. Yegen, Y. Eralp, A. Aydiner
Journal: Journal of Thoracic Oncology (2019)